PeptideTreatments
Reviewed by Peptide Treatments Medical Advisory Board (Medical Advisory Board)

Argireline: Research & Evidence

Established Evidence

Published research, clinical trial data, and evidence grading for Argireline across studied indications.

Back to Argireline overview

Research Summary

Argireline has 8+ published RCTs totaling over 500 subjects, with a 2017 systematic review showing modest efficacy (15-25% reduction) in wrinkle depth. Most studies are industry-funded by Lipotec/L'Oreal with small sample sizes. It is classified as a cosmetic ingredient, not an FDA-regulated drug, and independent head-to-head comparisons with Botox are lacking.

Evidence by Indication (3 indications)

Indication Tier Trials Summary
Wrinkle reduction Tier B 8 Multiple RCTs showing 15-30% wrinkle depth reduction
Crow's feet Tier B 3 Periorbital studies show ~20% improvement
Skin smoothing Tier C 2 Limited studies on general skin texture

Graded using our evidence tier methodology.

Citations (4 sources)

  1. 1. A synthetic hexapeptide (Argireline) with antiwrinkle activity Study

    Blanes-Mira C, et al. (2002), International Journal of Cosmetic Science

  2. 2. In vivo evaluation of the efficacy of Argireline in reducing periorbital wrinkles Study

    Ruetsch SB, et al. (2005), Journal of Cosmetic and Laser Therapy

  3. 3. Systematic review of topical cosmetic peptides for wrinkle reduction Review

    Multiple authors (2017), Journal of Cosmetic Dermatology

  4. 4. Cosmetic peptide review: efficacy and evidence assessment Review

    Multiple authors (2020), Dermatologic Therapy